The ability to write DNA efficiently is a key necessity for almost all applications in the life science industry. DNA synthesis enables the engineering of biological systems (enzymes, antibodies, bacteria, yeast, plants, cells, etc.) to create new applications, most notably in biotherapeutics, the production of chemicals and materials, agriculture or nanotechnology.
DNA Script is developing a novel enzymatic technology to synthesize DNA that will increase performance in strand length, purity, turnaround time and cost. This blog series reports key technological milestones — initially revealed at the GP-write Conference
in May 2018 — which demonstrate the potential of enzymatic synthesis, even at this early phase in the development of our technology. DNA Script reaches key performance milestone for enzymatic synthesis / Update on DNA Script performances and future milestones
Although enzymatic synthesis is still in its infancy, it is quickly catching up with phosphoramidite chemistry. Indeed, in less than 4 years, DNA Script has made tremendous progress, moving from an idea to the successful synthesis of real, functional DNA. This has been achieved thanks to the trust and support of private and public investors ($25M financing from Illumina Ventures, Merck Ventures, Sofinnova, Kurma, Idinvest, Bpifrance and the European Commission), but more importantly, thanks to a team of 30 people bringing a unique set of skills to the project.
DNA Script's achievements demonstrate the extremely quick pace of development, as well as the technology's promise: